At the Center for Translational Genomics, we are committed to translating insights from leading-edge genomic research into routine medical practice. Since the completion of the Human Genome Project in 2003, we have made great strides in understanding how different genetic markers influence health and disease. The field of genomics is now entering a new era of research in polygenic disease risk, given recent evidence that suggests that common disease risk is likely driven by hundreds or thousands of genetic markers combined. Translating polygenic associations into usable information for disease prediction, diagnosis, and treatment could greatly benefit the medical management of complex diseases, but this effort will require ongoing collaboration between those who are developing genetic tools and those who are bringing them directly to patients.
The Center for Translational Genomics facilitates crucial interactions between Mount Sinai researchers, clinicians, and external collaborators to develop, test, and implement polygenic risk tools. In our service-oriented center, projects are driven by the clinical interests of collaborators across the Mount Sinai Health System. Our goal is to provide computational support and domain expertise for polygenic risk projects along the continuum from research to clinical implementation.
We invite you to submit a research proposal and join us in our efforts to improve human health by harnessing the power of the whole genome.
Eimear E. Kenny, PhD
Founding Director, Institute for Genomic Health
Endowed Chair and Professor of Genomic Health